Reid Harrison, MD
Internal Medicine · Franklin, VANPI 1356373500
Payments from drug & device makers
Across 110 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$249
- AstraZeneca$202
- Pfizer$168
- Novo Nordisk$158
- Boehringer Ingelheim$125
- Lilly USA, LLC$109
- plus $636 from 23 others
What the payments were for
- Food & beverage$1,642100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $249 |
| AstraZeneca | 13 | $202 |
| Pfizer | 11 | $168 |
| Novo Nordisk | 12 | $158 |
| Boehringer Ingelheim | 8 | $125 |
| Lilly USA, LLC | 8 | $109 |
| Sanofi-aventis U.S. LLC | 7 | $92 |
| Johnson & Johnson | 6 | $90 |
| Amarin Pharma, Inc. | 3 | $47 |
| GSK | 2 | $46 |
| Amgen | 3 | $45 |
| Lundbeck LLC | 2 | $33 |
| Merck | 2 | $33 |
| Gilead | 2 | $32 |
| Mylan Specialty L.p. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Bioventus LLC | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Sobi, Inc | 1 | $13 |
| Hologic Sales And Service, LLC | 1 | $12 |
| Bayer | 1 | $12 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
| Teleflex LLC | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Sanofi Pasteur Inc. | 1 | $11 |
How this compares
$1,648 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 61 | $99,102 |
| JardianceEmpagliflozin | 52 | $73,243 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $55,369 |
| OzempicSemaglutide | 31 | $54,757 |
| EliquisApixaban | 40 | $42,001 |
| JanuviaSitagliptin Phosphate | 19 | $32,960 |
| XareltoRivaroxaban | 20 | $30,276 |
| MounjaroTirzepatide | 17 | $17,392 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $14,585 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $12,412 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $8,019 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $6,524 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 151 | $3,971 |
| Atorvastatin Calcium | 359 | $2,588 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 90 | $2,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $109 | $116,49478 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $125 | $81,26265 claims |
| GileadBiktarvy | $32 | $55,36912 claims |
| Novo NordiskOzempic | $158 | $54,75731 claims |
| MerckJanuvia, Janumet Xr | $33 | $45,37236 claims |
| PfizerEliquis | $168 | $42,00140 claims |
| Johnson & JohnsonXarelto | $90 | $30,27620 claims |
| GSKTrelegy Ellipta | $46 | $14,58522 claims |
| Sanofi-aventis U.S. LLCLantus | $92 | $1,90811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Franklin
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.